Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 April 2018 Photo Sonia Small
First-rate fund managers in SA produced by UFS Prof Philippe Burger
of Philippe Burger, Acting Dean of the Faculty of Economic and Management Science.

A recent comparative study on the performance of South African fund managers has revealed that the-top performing fund managers over a running average of five years are former undergraduate students of the University of the Free State (UFS).

In an attempt to understand South Africa’s fund managers, Leigh Köhler, head of research at Glacier by Sanlam, and his team, published a comprehensive breakdown which looked at all South African universities and universities of technology. Aspects explored in the report included philosophy, process, people, organisational structure, and cost of funds. In addition, the study also considered characteristics such as age, tenure, level of qualification and undergraduate university to identify fund managers who are superior to their peers.

A closer look at the statistics
The majority of the sampled fund managers studied at the University of Cape Town (46%), University of Stellenbosch (10%), and University of the Witwatersrand (8%), while only 2% studied at the UFS. However, according to the report, “The highest average performance over five years was generated by fund managers who attended the UFS – 13.25%.” This means that for every rand they invested, the portfolios managed by UFS alumni got back approximately R1.13 annually, the highest return when compared to the returns generated by portfolio managers from other universities. These fund managers are employed by a range of institutions, including independent asset management firms, insurance companies, banks and wealth managers.

What our acting dean had to say

Prof Philippe Burger, Acting Dean at the UFS Faculty of Economic and Management Science, said: “When you and I put money into a pension fund or investment, portfolio managers buy bonds and shares with it from companies. Those companies use that money to invest in building factories, businesses, offices, and of course they make a profit on their investments. That profit is used to pay interest and dividends. These interest payments, dividends and increased share values constitute the returns paid to investors.”

The outstanding performance of UFS-groomed fund managers is a comment on the quality of the students UFS delivers. “For decades we have had a BComm degree that includes an option to specialise in what was previously called Money and Banking, and is now called Financial Economics. We are the only faculty that has had a focus on Financial Economics going back all the way to the late 1970s. In that sense we train people and give them an education that allows them to perform like this,” said Prof Burger. 

Moving forward, the faculty is looking at partnerships with financial institutions that can strengthen that capacity and give students increased value for money. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept